Skip to main content
. 2022 Mar 14;28(6):1117–1126. doi: 10.1158/1078-0432.CCR-21-2733

Figure 1.

Figure 1. ORR in subgroups. aOf 15 patients with squamous cell histology; 9 (60.0%) had a smoking history and 6 (40.0%) were never smokers; 7 were from the United States (46.7%), 5 from Europe (33.3%), and 3 from Asia (20.0%). ‘Other’ histologies included sarcomatoid (n = 3), adenosquamous (n = 2), and NSCLC not otherwise specified (n = 1). bOne patient received ICI as monotherapy and in combination with platinum-based chemotherapy and, as such, is included in both subgroups. cPatients could have received first-line platinum-based chemotherapy followed by second-line single-agent ICI, or vice versa. dBrain metastases as identified by RECIST v1.1 criteria; systemic objective response per RECIST v1.1 criteria.

ORR in subgroups. aOf 15 patients with squamous cell histology; 9 (60.0%) had a smoking history and 6 (40.0%) were never smokers; 7 were from the United States (46.7%), 5 from Europe (33.3%), and 3 from Asia (20.0%). ‘Other’ histologies included sarcomatoid (n = 3), adenosquamous (n = 2), and NSCLC not otherwise specified (n = 1). bOne patient received ICI as monotherapy and in combination with platinum-based chemotherapy and, as such, is included in both subgroups. cPatients could have received first-line platinum-based chemotherapy followed by second-line single-agent ICI, or vice versa. dBrain metastases as identified by RECIST v1.1 criteria; systemic objective response per RECIST v1.1 criteria.